Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde

PHASE4CompletedINTERVENTIONAL
Enrollment

242

Participants

Timeline

Start Date

May 9, 2019

Primary Completion Date

November 30, 2020

Study Completion Date

November 30, 2020

Conditions
Malaria,Falciparum
Interventions
DRUG

Artesunate-amodiaquine combination

Artesunate-amodiaquine (Coarsucam®: Sanofi-Aventis, France) is co-packaged as artesunate 50 mg and amodiaquine hydrochloride USP equivalent to amodiaquine base of 153.1 mg. Each child shall be given one, two or three tablets depending on the weight.

DRUG

Artemether, Lumefantrine Drug Combination

Artemether-lumefantrine (Coartem®: Novartis, Switzerland) is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains two blisters for each day with one, two or three tablets depending on the weight of the child

Trial Locations (1)

+237

District Medical Center Minkoa Meyos, Yaoundé

All Listed Sponsors
collaborator

Malaria Research Capacity Development in West and Central Africa Consortium

UNKNOWN

collaborator

Developing Excellence in Leadership, Training and Science Africa Initiative

UNKNOWN

collaborator

Wellcome Trust

OTHER

collaborator

United Kingdom Department for International Development

UNKNOWN

lead

University of Yaounde 1

OTHER

NCT04565184 - Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde | Biotech Hunter | Biotech Hunter